GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BioCryst
BioCryst Pharmaceuticals specializes in treating rare diseases. Its share price is driven by sales of its lead drug, Orladeyo, and progress in developing other drugs. The stock price is a classic biotech story, with value dependent on commercial and clinical success.
Share prices of companies in the market segment - Pharma immune
BioCryst Pharmaceuticals specializes in treating rare diseases. Its core business is the commercialization of Orladeyo. We classify it as part of the Pharma-Immune sector, and the chart below shows the dynamics of the entire segment, as well as the sales growth history of this key drug.
Broad Market Index - GURU.Markets
BioCryst Pharmaceuticals is a biotechnology company that develops and markets drugs to treat rare and serious diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how its product commercialization successes impact its stock price.
Change in the price of a company, segment, and market as a whole per day
BCRX - Daily change in the company's share price BioCryst
BioCryst, a biopharmaceutical company, has volatility measured by change_co. It reflects its sensitivity to sales of its rare disease drugs and laboratory news. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
BioCryst Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with BCRX, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
BioCryst is a biopharmaceutical company specializing in drugs for rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing BioCryst's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BioCryst
BioCryst is a biopharmaceutical company specializing in the treatment of rare diseases. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Pharma immune
BioCryst Pharmaceuticals, Inc. is a commercial biopharmaceutical company specializing in the treatment of rare diseases. Its success depends on the commercialization of its approved drugs and the results of R&D. The chart shows how its focus on orphan diseases and the competitive environment influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioCryst is a biopharmaceutical company whose stock performance is driven by sales success of its drugs for rare diseases and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BioCryst
BioCryst, a biopharmaceutical company specializing in rare diseases, has monthly fluctuations on the chart reflecting the commercial success of its drugs, as well as news about clinical trials of new candidates in its pipeline.
Monthly dynamics of market capitalization of the market segment - Pharma immune
BioCryst Pharmaceuticals develops drugs to treat rare diseases by inhibiting enzymes that play a key role in disease progression. Their lead product is designed to combat hereditary angioedema. The chart below shows the overall dynamics of the orphan disease biotechnology sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioCryst is a biotech company with approved drugs for rare diseases. Its dynamics are hybrid: on the one hand, they depend on sales growth for existing drugs, and on news about future developments, on the other. This makes it less speculative than clinical biotechs, but still volatile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BioCryst
BioCryst Pharmaceuticals' weekly performance reflects the fight against rare diseases. This biotech company's stock price is responding to the commercial success of its hereditary angioedema treatment and news from its research pipeline.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Biotech focused on rare diseases is a sector where weekly performance depends on the commercial success of niche drugs. Progress in developing new drugs is a common driver for all. The chart illustrates this backdrop, which can be used to evaluate BioCryst's portfolio.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioCryst Pharmaceuticals specializes in treating rare diseases. Shares of such innovative biotech companies often move independently of the market, responding to scientific data. This chart will help you understand: is BioCryst living in its own world of clinical trials, or are overall market conditions and risk appetite influencing its stock price?
Market capitalization of the company, segment and market as a whole
BCRX - Market capitalization of the company BioCryst
BioCryst's market capitalization chart tells the story of rare disease drug development, with the commercial success of Orladeyo, a drug for the treatment of hereditary angioedema, playing a key role. Its dynamics reflect the growth of this drug's sales, as well as progress in the development of other drugs, including those for viral diseases.
BCRX - Share of the company's market capitalization BioCryst within the market segment - Pharma immune
BioCryst Pharmaceuticals specializes in developing drugs for rare diseases. Its market share reflects the success of its commercial drugs and the potential of its development pipeline. The chart shows how its focus on orphan diseases allows the company to achieve leadership positions in its therapeutic niches.
Market capitalization of the market segment - Pharma immune
BioCryst Pharmaceuticals is a company developing and commercializing drugs for the treatment of rare diseases. The chart below shows the overall market capitalization of the biotech sector. Its dynamics reflect both the risks of development and the commercial success of approved drugs, as in the case of BioCryst.
Market capitalization of all companies included in a broad market index - GURU.Markets
BioCryst develops small-molecule drugs for the treatment of rare diseases. Its market capitalization reflects its success in this complex area of pharmaceuticals. The chart below shows the economic weight of companies developing tablet formulations of drugs for orphan diseases.
Book value capitalization of the company, segment and market as a whole
BCRX - Book value capitalization of the company BioCryst
BioCryst's book value is the capital it invests in commercializing drugs for rare hereditary diseases and developing new molecules. This is a solid, scientific foundation, targeting niche but important markets. How has this biotech asset evolved? The chart below reveals its volatile yet fascinating history.
BCRX - Share of the company's book capitalization BioCryst within the market segment - Pharma immune
BioCryst develops drugs for rare diseases, which requires specialized research laboratories. The graph shows the share of these science-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation upon which the company creates its innovative molecules.
Market segment balance sheet capitalization - Pharma immune
Developing drugs to treat rare diseases, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. BioCryst Pharmaceuticals operates in this environment. Its capital is invested in the scientific platform and the commercialization of already approved products, rather than in giant manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
BioCryst Pharmaceuticals' book value is derived from its intellectual property and research facilities focused on rare diseases. It reflects the capital invested in the scientific foundation that enables the development and commercialization of drugs that have a significant material impact on patients' lives.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BioCryst
BioCryst Pharmaceuticals develops drugs for rare diseases. The company's book value is primarily cash, while its market value is the valuation of its existing and future drugs. The MvsBCap chart shows investor confidence in sales growth and clinical trial success, which are the biotech company's primary drivers.
Market to book capitalization ratio in a market segment - Pharma immune
BioCryst Pharmaceuticals develops drugs to treat rare diseases. The company's value is determined by the success of its commercialized drugs and the potential for future developments. This metric reflects the premium the market pays for its orphan drug portfolio and scientific platform.
Market to book capitalization ratio for the market as a whole
BioCryst Pharmaceuticals develops drugs to treat rare diseases. Its valuation is a classic biotech example, with a market capitalization that exceeds its book value multiple times. Investors aren't buying assets, but rather the potential of its research and development and the future revenue streams from successful drugs, as this chart demonstrates.
Debts of the company, segment and market as a whole
BCRX - Company debts BioCryst
BioCryst Pharmaceuticals is raising funds to finance the commercial launch of its drugs and research into new molecules. Focusing on rare diseases means high R&D and marketing costs. This chart shows how the company manages its finances to bring life-saving drugs to market and ensure future growth.
Market segment debts - Pharma immune
BioCryst Pharmaceuticals develops and commercializes drugs for rare diseases. The transition from research to sales changes the company's financial profile. Debt can be used to finance marketing and further development. This chart provides insight into how the company manages its finances during the commercialization phase.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BioCryst
BioCryst Pharmaceuticals develops drugs for rare diseases. The chart shows how the company finances its expensive developments. For a biopharma company that spends heavily on R&D before turning a profit, debt is a risky source of capital. Its level reflects the market's confidence in the future success of its drugs.
Market segment debt to market segment book capitalization - Pharma immune
BioCryst Pharmaceuticals develops drugs for rare diseases, which requires high R&D costs. This pharmaceutical industry chart shows how companies finance their long-term research programs. It provides context for assessing the company's financial strategy and risks in its quest to develop new drugs.
Debt to book value of all companies in the market
BioCryst is a biotech company. Its funding depends on investors' confidence in future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt- or equity-based financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - BioCryst
This chart of BioCryst Pharmaceuticals, a company specializing in rare diseases, reflects investor confidence in its drug portfolio. High values indicate that the market is assessing not only current sales but also the potential of future drugs, each of which could become blockbusters in its niche.
P/E of the market segment - Pharma immune
This chart shows the average P/E for the biopharmaceutical industry, where BioCryst specializes in rare diseases. The high average valuation of the sector reflects the potential for blockbusters. This metric helps understand whether the market values BioCryst's drug portfolio at a premium or discount to other biotech companies.
P/E of the market as a whole
BioCryst Pharmaceuticals develops drugs to treat rare diseases with unmet medical needs. The company has both approved products and promising pipelines. This chart, showing overall risk appetite, allows investors to assess how BioCryst's current revenue compares to the potential of its future drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BioCryst
BioCryst Pharmaceuticals develops and commercializes drugs for the treatment of rare diseases. The chart reflects future revenue expectations, which depend on sales growth for already approved drugs and the success of clinical trials for new candidates. The market is assessing whether the company can convert its scientific research into stable cash flows.
%20P%2FE%20BioCryst&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BioCryst&v=1772552336380 "Chart of the company's future (projected) P/E BioCryst")
Future (projected) P/E of the market segment - Pharma immune
BioCryst Pharmaceuticals develops small-molecule drugs for the treatment of rare diseases. Its pipeline includes both approved products and candidates in development. This chart compares BioCryst's future profitability expectations with the industry. It allows one to assess the market's confidence in the commercial success of its current and future drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772552336392 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
BioCryst Pharmaceuticals develops drugs to treat rare diseases. Its business model is based on scientific research and the commercialization of unique drugs. This graph of overall risk appetite shows how inclined investors are currently to invest in the biotech sector, with its high potential returns and risks.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772552336437 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BioCryst
BioCryst Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of rare diseases. The company's profits depend on sales of its approved drugs and the progress of new candidates in clinical trials. This chart shows the financial trajectory of the company, which focuses on niche but vital therapeutic areas.
Profit of companies in the market segment - Pharma immune
BioCryst Pharmaceuticals specializes in developing small-molecule drugs for rare diseases. Its portfolio includes drugs for hereditary angioedema. This chart reflects the overall profitability of the orphan disease niche, where companies can gain market exclusivity and command high prices for their drugs.
Overall market profit
BioCryst Pharmaceuticals develops drugs to treat rare diseases. The company's success depends on regulatory approval of its drugs and their subsequent introduction into clinical practice. This process is isolated from economic cycles, as illustrated by this chart. Demand for life-saving drugs is inelastic, providing the company with stability during periods of market volatility.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BioCryst
BioCryst Pharmaceuticals develops and commercializes small molecule drugs for the treatment of rare diseases. Future revenue depends on the market success of its drugs and progress in clinical development. This chart reflects analyst expectations for sales growth of existing products and the potential of new candidates in the company's pipeline.
%20profit%20of%20the%20company%20BioCryst&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BioCryst&v=1772552336556 "Graph of future (projected) profit of the company BioCryst")
Future (predicted) profit of companies in the market segment - Pharma immune
BioCryst Pharmaceuticals develops and commercializes drugs for the treatment of rare diseases. Its portfolio includes drugs for hereditary angioedema. The company's success depends on sales of existing products and the development of new ones. This chart shows revenue projections for the immunopharmaceuticals sector, providing context for evaluating BioCryst's niche strategy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772552336583 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
BioCryst Pharmaceuticals develops and markets drugs for rare diseases. Its financial performance depends on sales of existing drugs and the success of new developments. The overall economic environment, shown in this chart, impacts the healthcare system and its ability to finance costly innovative treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772552336585 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BioCryst
BioCryst Pharmaceuticals develops drugs to treat rare diseases. Revenue from approved drugs is vital to funding further research. This chart shows how investors balance current sales valuations with the potential of the company's future products in development.
P/S market segment - Pharma immune
BioCryst Pharmaceuticals specializes in the development and commercialization of oral medications for rare diseases. Their approach allows patients to take medications in a convenient form, significantly improving their quality of life. This chart reflects the average revenue estimate in the pharmaceutical sector, providing insight into how the market values BioCryst's innovations and product portfolio.
P/S of the market as a whole
BioCryst Pharmaceuticals develops and commercializes drugs for rare diseases. The company has both approved products and promising pipelines. This chart helps assess the premium investors are placing on its orphan drug portfolio, where prices are high and competition is lower, compared to the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BioCryst
BioCryst Pharmaceuticals develops and commercializes small-molecule drugs for the treatment of rare diseases. Estimating future revenue is crucial for such a company. It reflects investor expectations for sales growth of already approved drugs and the success of clinical trials of other candidates in the pipeline, which could become new revenue sources.
%20P%2FS%20BioCryst&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BioCryst&v=1772552336649 "The graph of the company's future (projected) P/S BioCryst")
Future (projected) P/S of the market segment - Pharma immune
BioCryst Pharmaceuticals develops and commercializes small-molecule drugs for the treatment of rare diseases. Its key product is designed to prevent attacks of hereditary angioedema. This chart compares the company's estimated future revenue with other biotech companies and reflects investor expectations for sales growth of its drug.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772552336667 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
BioCryst Pharmaceuticals develops drugs to treat rare diseases. The company's success depends on scientific developments and regulatory approvals. In the overall revenue growth picture illustrated by the chart, BioCryst represents an innovative sector whose contribution to the economy could be significant in the future.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772552336689 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BioCryst
The graph illustrates the revenue of BioCryst Pharmaceuticals, a company developing drugs for rare diseases. Revenue is generated primarily from sales of ORLADEYO, a drug for the prevention of hereditary angioedema attacks. The growth in this indicator reflects the successful launch of the product and the increasing number of patients receiving the therapy.
Sales of companies in the market segment - Pharma immune
BioCryst Pharmaceuticals specializes in developing drugs for rare diseases. Its revenue breakdown shows that its primary revenue source is ORLADEYO, a drug for the treatment of hereditary angioedema. This demonstrates the company's successful strategy of entering niche markets with high unmet needs.
Overall market sales
BioCryst Pharmaceuticals develops drugs to treat rare diseases. The company operates in a field where demand is driven by medical need, not economic conditions. This graph of overall market activity highlights the difference between BioCryst, whose value is generated by scientific breakthroughs, and companies dependent on consumer cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BioCryst
BioCryst Pharmaceuticals develops and commercializes small-molecule drugs for the treatment of rare diseases. The company's revenue growth depends on sales of its approved products and the success of clinical trials of new candidates. This chart illustrates analysts' forecasts for current and future revenue streams, reflecting their assessment of the market potential of its drug portfolio.
%20sales%20of%20the%20company%20BioCryst&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BioCryst&v=1772552336777 "Schedule of future (projected) sales of the company BioCryst")
Future (projected) sales of companies in the market segment - Pharma immune
BioCryst Pharmaceuticals develops drugs to treat rare diseases. This chart shows sales forecasts for the biotech sector. Do analysts expect the orphan drug market to grow thanks to government support and scientific breakthroughs? This allows us to assess how favorable the overall trend is for BioCryst's business model.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772552336798 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
BioCryst Pharmaceuticals develops drugs to treat rare diseases. The company's success depends on the approval of its drugs and their acceptance by the medical community. Demand for orphan disease therapies is inelastic and independent of economic cycles. Therefore, this graph, reflecting consumer spending, has virtually no impact on BioCryst's core business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772552336799 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BioCryst
BioCryst Pharmaceuticals develops and markets small-molecule drugs for the treatment of rare diseases. This chart shows the financial trajectory of the company bringing orphan drugs to market. Its profitability depends on the successful commercialization of its products and the ability to charge high prices justified by their uniqueness and the lack of alternatives for patients.
Market segment marginality - Pharma immune
BioCryst Pharmaceuticals, Inc. specializes in developing drugs for rare diseases. Its business model is based on scientific research and the commercialization of innovative drugs. This metric reflects the company's financial performance, where profitability depends on the commercial success of its approved products and the progress of new candidates in clinical trials.
Market marginality as a whole
BioCryst Pharmaceuticals develops drugs for rare diseases. Its financial health depends on the success of research and commercialization of these drugs. This overall profitability chart reflects the investment climate. During periods of economic growth, investors are more willing to fund biotech companies, which is critical for BioCryst.
Employees in the company, segment and market as a whole
Number of employees in the company BioCryst
BioCryst Pharmaceuticals develops and markets drugs for rare diseases. Its staff includes both researchers and a commercial team. This chart shows how the company is expanding its global sales team to promote its approved drug while simultaneously investing in R&D to develop new drugs in its pipeline.
Share of the company's employees BioCryst within the market segment - Pharma immune
BioCryst Pharmaceuticals develops and markets drugs for rare diseases. The company has evolved from a purely research-based organization to a commercial one, requiring the hiring of not only scientists but also marketing and sales specialists. This graph shows the company's labor market share, and its growth may indicate successful product launches.
Number of employees in the market segment - Pharma immune
BioCryst Pharmaceuticals develops small-molecule therapies for rare diseases with unmet medical needs. This chart reflects the company's presence in the immunopharmaceuticals sector. BioCryst's focus on orphan diseases allows the company to occupy unique market niches with significant pricing power.
Number of employees in the market as a whole
BioCryst Pharmaceuticals develops drugs to treat rare diseases. The growth of its scientific and commercial teams reflects the transition from research to sales. Unlike the overall employment in this chart, the hiring dynamics at BioCryst are a story of the success of a specific drug and its market launch.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BioCryst (BCRX)
BioCryst develops drugs for rare diseases. This chart shows how the market values their expertise in this niche. The company's value is concentrated in their approved products and development pipeline. The high market capitalization per employee reflects the high margins of orphan drug treatments and the value of their intellectual property.
%20of%20the%20company%20BioCryst%20(BCRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BioCryst-BCRX&v=1772552337066 "Chart of market capitalization per employee (in thousands of dollars) of the company BioCryst (BCRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
BioCryst Pharmaceuticals (BCRX) is a company specializing in developing oral therapies for rare diseases. Their key product is ORLADEYO (angioedema treatment). This chart shows the industry average cost per employee. It helps assess how the market values their commercial product and R&D platform per scientist.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772552337072 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
BioCryst Pharmaceuticals develops drugs to treat rare diseases. The company's value is determined by its scientific developments and pipeline. This chart shows a high valuation per employee, typical for the biotech sector, where a small team of scientists can create a product with potential for billions of dollars in sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772552337078 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BioCryst (BCRX)
BioCryst is a pharmaceutical company specializing in rare diseases. The company has commercially available drugs. This chart shows how effectively the company monetizes its research and development. It reflects how much net profit the team generates from sales of its niche, high-margin drugs, while still covering R&D costs.
%20Chart%20BioCryst%20(BCRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BioCryst-BCRX&v=1772552337127 "Company Profit Per Employee (in thousands of dollars) Chart BioCryst (BCRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
BioCryst (BCRX) is an R&D biotech company (rare diseases). This chart shows the benchmark for "Immune Pharma" (R&D). The average profit per employee in this sector (biotech) is high (if there's a hit). The benchmark reflects a "one-hit business": the sector spends millions on R&D, and a single successful orphan drug recoups all costs.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772552337178 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
BioCryst Pharmaceuticals is a biopharmaceutical company with an approved drug (Orladeyo) for the treatment of a rare genetic disease. It's a single-product business. This chart shows how well sales of this drug cover the enormous R&D costs of other areas. It's a balance between commercialization and future innovation.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772552337193 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BioCryst (BCRX)
BioCryst Pharmaceuticals develops drugs for rare diseases. This chart is an indicator of their commercial success. The sharp increase in revenue per employee after the drug's launch demonstrates how the intellectual property created by the scientific team is converted into significant cash flow thanks to the high value of orphan drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BioCryst-BCRX&v=1772552337235 "Sales chart per company employee BioCryst (BCRX)")
Sales per employee in the market segment - Pharma immune
BioCryst Pharmaceuticals specializes in drugs for the treatment of rare (orphan) diseases. They have approved products. This chart shows the average production in the sector. For BCRX, this is an indicator of how productive their R&D and commercialization team is in developing and commercializing drugs for the niche but high-margin rare disease markets.
Sales per employee for the market as a whole
BioCryst Pharmaceuticals develops and markets drugs for rare diseases. Their business model is based on R&D and commercialization of niche drugs. This chart shows how effectively their research translates into sales. It's a balance between high R&D costs and the high price of orphan drugs.
Short shares by company, segment and market as a whole
Shares shorted by company BioCryst (BCRX)
BioCryst (BCRX) is a pharmaceutical company specializing in rare diseases. Its key drug treats hereditary angioedema. This chart shows the number of bearish bets. Investors who are bearish on the drug may be skeptical of its long-term sales potential or the success of the company's other early-stage developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BioCryst-BCRX&v=1772552337323 "Short Shares Chart for the Company BioCryst (BCRX)")
Shares shorted by market segment - Pharma immune
BioCryst (BCRX) specializes in developing oral medications for rare diseases, particularly hereditary angioedema (HAE). This chart shows the total short position in the biotech sector. It reflects investor concerns about intense competition or difficulties with reimbursement for expensive drugs.
Shares shorted by the overall market
BioCryst (BCRX) is a biotech focused on rare diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk. Biotech stocks, even those with approved drugs, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BioCryst (BCRX)
BioCryst (BCRX) is a biopharmaceutical company that develops and commercializes drugs for rare diseases. Their key product is Orladeyo, a treatment for hereditary angioedema. This chart measures hype. It shows when strong sales growth for Orladeyo leads to an overbought condition (above 70) or when concerns about R&D costs lead to an oversold condition (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BioCryst-BCRX&v=1772552337401 "RSI 14 indicator chart for the company's stock BioCryst (BCRX)")
RSI 14 Market Segment - Pharma immune
BioCryst (BCRX) is a biotech company developing oral (tablet-based) drugs for rare diseases, like Orladeyo. The RSI_14_Seg for "Pharma-immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether BCRX's growth reflects commercial success or general hype.
RSI 14 for the overall market
BioCryst (BCRX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BCRX (BioCryst)
BioCryst Pharmaceuticals specializes in developing oral medications (in tablet form) for the treatment of rare diseases. Its key product, Orladeyo, is designed to prevent attacks of hereditary angioedema. This chart shows the average analyst forecast. Their target prices are based on Orladeyo sales growth and the progress of other programs in development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BCRX-BioCryst&v=1772552337409 "A chart showing analyst consensus forecasts for the expected stock price. BCRX (BioCryst)")
The difference between the consensus estimate and the actual stock price BCRX (BioCryst)
BioCryst Pharmaceuticals is a commercial biotech company focused on rare diseases. Their lead product, Orladeyo, is the world's first daily pill to prevent attacks of hereditary angioedema (HAE). This chart shows analysts' estimates of the market penetration of this convenient drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BCRX-BioCryst&v=1772552337415 "A chart showing the difference between the consensus forecast and the actual stock price. BCRX (BioCryst)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
BioCryst Pharmaceuticals is a biotech company specializing in the development of oral medications for rare diseases. Its lead product is ORLADEYO, a treatment for hereditary angioedema. This chart shows general expectations for the immune pharma sector, reflecting whether experts believe the drug will see sales growth.
Analysts' consensus forecast for the overall market share price
BioCryst Pharmaceuticals is a company developing and commercializing drugs for rare diseases. Their flagship drug is ORLADEYO, an oral treatment for the prevention of attacks of rare edema (HAE). This chart shows overall market sentiment. For BioCryst, which focuses on rare diseases, it's important to understand how these expectations (healthcare budgets) impact demand for their expensive drug. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BioCryst
BioCryst (BCRX) is a biopharmaceutical company focused on rare diseases. Their key product, Orladeyo, is an oral medication (tablet) for the treatment of a rare edematous disease (HAE). This chart is an indicator of the commercial battle. It measures their success in switching patients from traditional injections to the convenience of their daily pill.
AKIMA Market Segment Index - Pharma immune
BioCryst (BCRX) is a commercial biotech focused on rare diseases; the company successfully launched an oral drug (Orladeyo) for the prevention of HAE (angioedema) attacks. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche model (HAE) differentiate BCRX from the average pharma company?
The AKIM Index for the overall market
BioCryst is a biotech company specializing in rare diseases. Its key product is Orladeyo (hereditary angioedema). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is transitioning to profitability, compares to overall economic trends.
